Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

GSK Launches Discovery Fast Track Competition for Academic Researchers

Published: Wednesday, May 22, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
Scientists in U.S., Canada challenged to submit groundbreaking research proposals for chance at collaborative partnership focused on drug discovery.

GlaxoSmithKline plc (GSK) announced the launch of Discovery Fast Track, a competition designed to accelerate the translation of academic research into novel therapies. Winners of the competition will partner with investigators on GSK’s Discovery Partnerships with Academia (DPAc) team with a goal of developing viable research-stage drug candidates into innovative medicines.

Launched in the U.K. in late 2010, the DPAc program is a new approach to drug discovery where academic partners become core members of drug-hunting teams. GSK and the academic partner share the risk and reward of innovation, where GSK funds activities in the partner laboratories, as well as provides in-kind resources to progress a program from an idea to a candidate medicine. DPAc’s reach is global. To date, GSK has initiated nine collaborations in nine disease areas, including two in the U.S. and one in Canada.

"DPAc programs are incredibly valuable,” said Roger Cone, professor of molecular physiology and biophysics at Vanderbilt University School of Medicine and a DPAc participant. “Pharmaceutical companies bring an industrial approach to drug discovery that can’t be replicated in academia. Combined with the pharmacological and biological expertise of academia, it’s a perfect combination of skills and resources."

To avoid initial contract negotiations, which are often perceived as the biggest bottleneck in the Pharma/academia collaborative process, the DPAc team conceived the Discovery Fast Track competition as a means to rapidly identify and screen the most promising hypotheses in academia.

“With the Discovery Fast Track competition, we want to give all academic researchers who are passionate about translating their science into therapy, a chance to collaborate and access GSK resources and expertise to help bring novel and transformative treatments to patients,” said Pearl Huang, Ph.D., Global Head of DPAc. “We are excited to receive submissions in all therapeutic areas and look forward to being part of the researcher’s journey in making a difference.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK Announces £275M UK Investment
GSK has announced £275 million of new manufacturing site investment to boost production and support product delivery.
Friday, July 29, 2016
GSK, Idera to Collaborate
Idera to collaborate with GSK to identify 3rd generation antisense molecules for treatment of renal disease.
Monday, November 30, 2015
GSK to Fully Acquire Cellzome for £61 Million
GSK to further expand its platform technology expertise with acquisition of chemical proteomics company.
Wednesday, May 16, 2012
Scientific News
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos